pseudobulbar

pseudobulbar

 [soo″do-bul´bar]
apparently, but not really, due to a bulbar lesion.

pseu·do·bul·bar

(sū'dō-bŭl'bar),
Denoting a supranuclear paralysis of the bulbar nerves.

pseudobulbar

/pseu·do·bul·bar/ (-bul´bar) apparently, but not really, due to a bulbar lesion.

pseu·do·bul·bar

(sū'dō-bŭl'bahr)
Denoting a supranuclear paralysis of the bulbar nerves.

pseudobulbar

apparently, but not really, due to a lesion of the medulla oblongata.
References in periodicals archive ?
org/about-pba) pseudobulbar affect syndrome and may be expressed in several different neurological conditions.
Pseudobulbar affect (PBA) is a neurologic condition that can happen after a patient has had some kind of neurological insult.
Pseudobulbar affect (PBA) is a disorder of affective expression that manifests as stereotyped and frequent outbursts of crying (not limited to lacrimation) or laughter.
Also in July, I covered a report at the Alzheimer's Association International Conference 2015 on the off-label use for treating agitation in Alzheimer's disease patients with the combination of dextromethorphan and quinidine, a formulation branded as Nuedexta with FDA approval for treating pseudobulbar affect.
Twenty-four hours post podophyllin ingestion, the child's GCS remained 5/15; however, he had now developed abnormal neurological signs, including hypotonia, areflexia with no clonus and reduced power in all limbs, but with no evidence of a pseudobulbar palsy.
She has been told she has pseudobulbar affect, or PBA.
The drug, Nuedexta, is already approved for pseudobulbar affect and is being investigated as AVP-923 for several other indications, including depression, migraine, neuropathic pain, autism, and Parkinson's disease dyskinesia.
The acquisition integrates the buyer's psychiatric products, led by the anti-psychotic AbilifyA (aripiprazole), with Avanir's marketed Nuedexta, a mix of dextromethorphan and quinidine that is FDA's first approved treatment indicated for Pseudobulbar Affect (PBA), and several Avanir drug candidates.
This law suit is in connection with Par Pharmaceuticals and Impax Laboratories' Abbreviated New Drug Applications (ANDAs) for generic versions of Avanir's US FDA approved NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect.
Avanir's NUEDEXTA (dextromethorphan HBr and quinidine sulfate) has been cleared by the US Food and Drug Administration (FDA) for the treatment of pseudobulbar affect.
Enna's constant giggling is called the Pseudobulbar effect - where patients who have had brain tumour surgery often express involuntary emotions.
The involuntary giggling is known as pseudobulbar affect and is thought to be caused by disruptions to nerves during surgery.